Gastrointestinal Cancer News

Adagrasib induced promising clinical activity as monotherapy among pretreated patients with unresectable or metastatic pancreatic cancer and other gastrointestinal tumors that harbor a KRAS G12C mutation, according to study results.

Adagrasib induced promising clinical activity as monotherapy among pretreated patients with unresectable or metastatic pancreatic cancer and other gastrointestinal tumors that harbor a KRAS G12C mutation, according to study results.

Fam-trastuzumab deruxtecan-nxki significantly extended OS compared with chemotherapy among patients from Japan and South Korea with HER2-positive gastric cancer, according to results presented at ASCO Gastrointestinal Cancers Symposium.

The addition of docetaxel to cisplatin and 5-FU chemotherapy significantly extended OS as neoadjuvant therapy for local advanced esophageal squamous cell cancer, according to results of a randomized phase 3 trial.

Nivolumab plus chemotherapy continued to confer clinically meaningful improvement in OS and PFS as first-line therapy for advanced gastric and esophageal cancers, according to a study presented at Gastrointestinal Cancers Symposium.

Patients with IgG4-related disease are at a higher risk for cancer — particularly pancreatic and lymphoma — compared with the general population, according to a meta-analysis published in Arthritis Research & Therapy.

Neoadjuvant treatment with nivolumab and ipilimumab led to a high rate of pathologic complete response among patients with resectable microsatellite instability-high/mismatch repair deficient gastric cancers, study results showed.

In a Healio video exclusive, John Inadomi, MD, president of the American Gastroenterological Association, outlined the Biden administration’s new guidance requiring private insurers to cover the cost of follow-up colonoscopy.

Hepatic arterial infusion pump (HAIP) chemotherapy, developed in the 1980s, has shown efficacy as an advanced treatment option for primary and secondary hepatic malignancies.

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma, according to a phase 3 study conducted in Asia.